Newsletter

You are here

Health, Scientific progress

28 - 04 - 2016

An anti-cancer drug corrects the cognitive impairment in a mouse model of fragile X

An anti-cancer drug named Nutlin-3 has corrected the cognitive impairment observed in a mouse model of fragile X syndrome, the most common cause of inherited mental retardation. Nutlin-3 is currently being used in a clinical trial for a rare tumour of the eye. This discovery illustrates the advances of researchers in the field of cognitive impairment. Click for more information